A clinical-stage biotechnology company in immunotherapy

Focused on developing and partnering therapies to control the immune system for Immuno-Oncology and Immuno-Inflammation.

Our latest press release

Read more

22/09/2022

OSE Immunotherapeutics Announces Corporate Update and H1 2022 Results

Download

To receive OSE Immunotherapeutics’ latest news